# Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination

> **NCT00160316** · PHASE3 · COMPLETED · sponsor: **Solvay Pharmaceuticals** · enrollment: 454 (actual)

## Conditions studied

- Postmenopause

## Interventions

- **DRUG:** 0.5 Mg Estradiol and 2.5 Mg Dydrogesterone

## Key facts

- **NCT ID:** NCT00160316
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 454 (ACTUAL)
- **Last updated:** 2008-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00160316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00160316, "Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00160316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*